Codexis (CDXS) 2025 Conference June 04, 2025 03:10 PM ET Speaker0 think we're good to go. I'm Tycho Peterson from the life science team. It's my pleasure to introduce Codexis. Happy to have Stephen Dully with us again this year. Stephen, maybe just to kick it off, obviously a lot of focus on ecosystem. Maybe let's go back twenty four months since the platform was just getting started. Walk us through the journey there, lots happened. How do we go from kind of technology and concept to execution of commercia ...

Codexis (CDXS) Conference Call Summary - May 22, 2025 Company Overview - **Company**: Codexis (CDXS) - **Industry**: Biotechnology, specifically focusing on siRNA (small interfering RNA) technology and enzymatic synthesis for genomic medicines Key Points and Arguments Industry Trends - **Surge in Demand for siRNA Therapeutics**: There is a recognized increase in demand for siRNA therapeutics, with significant interest in innovative manufacturing solutions [5][6] - **Shift Towards Enzymatic Synthesis**: The industry is moving towards enzymatic synthesis methods, which are seen as necessary to meet the scalability and purity requirements for siRNA production [6][18] Codexis Technology and Developments - **Ecosynthesis Technology**: Codexis' Ecosynthesis platform is positioned as a timely solution to the limitations of traditional solid-phase chemistry, with advancements in scalability and cost-effectiveness [10][18] - **Validation from Industry Leaders**: Codexis received external validation from major oligonucleotide manufacturers, highlighting the effectiveness of its double-stranded RNA ligase [6][7] - **Machine Learning Tool**: A newly developed machine learning tool aids customers in optimizing RNA fragment designs, demonstrating superior performance in identifying effective solutions [12][41] Customer Engagement and Market Position - **Increased Customer Interest**: There has been a notable shift in customer engagement, with decision-makers in process development now actively exploring Codexis' enzymatic solutions [17][18] - **Growing Customer Base**: The number of substantive discussions with potential customers has increased significantly, from single digits to over 20 prospects [20] - **Innovation Lab Capacity**: Codexis aims to fill its Eco Innovation Lab capacity with multiple customers, focusing on a diverse range of products [35][36] Competitive Landscape - **Leadership in Enzymatic Technology**: Codexis is recognized as a leader in enzymatic technology for siRNA manufacturing, with expectations to maintain this position through continued advancements [21][18] Future Outlook - **Partnerships and Collaborations**: Codexis is on track to sign a GMP scale-up partnership and anticipates selling its Eco Innovation Labs capacity by year-end [20] - **Focus on Stereochemistry Control**: The ability to control stereochemistry in siRNA production is seen as a significant advantage, allowing for the development of more effective therapeutic candidates [31][52] Additional Important Insights - **Transition from Proof of Concept to Production**: Codexis is moving from demonstrating proof of concept to establishing a practical production platform, emphasizing the importance of cycle times in manufacturing [27][28] - **Impact of Stereochemistry on Efficacy**: The control of stereochemistry is crucial for ensuring the activity and effectiveness of siRNA therapeutics, with implications for both existing and new products [50][52] This summary encapsulates the key discussions and insights from the Codexis conference call, highlighting the company's strategic positioning within the biotechnology industry and its advancements in siRNA technology.

 Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases Management to host conference call today at 8 am Eastern Time to discuss data REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis’ ...

Codexis (CDXS) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Carrie McKim - Director of Investor RelationsStephen Dilly - President, CEO & ChairmanStefan Lutz - Senior Vice President of ResearchGeorgia Erbez - Chief Financial OfficerTycho Peterson - Managing Director, Global EquitiesDan Arias - Managing Director Conference Call Participants Kristen Kluska - Equity Research AnalystAllison Bratzel - Senior Research AnalystMatthew Hewitt - Senior Research AnalystBrendan Smith - Director & ...

Codexis (CDXS) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to your host, Carrie McKim, Director of Investor Relations. Carrie, please go ahead. Speaker1 Thank you, operator. With me today are Doctor. Stephen Dilly, Codexis' Chairman and Chief Executive Officer Georgia Erbez, Chief Financial Officer and Doctor. Stephane Lutz, Senior Vice President of Research. During this call, management will making a nu ...

Corporate Presentation May 2025 Forward Looking Statements These slides contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identif ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) _____________________________________________ Delaware 71-0872999 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 200 Penobscot Drive, Redwood City, California 94063 (Address of principal executive offices) (Zip Code) ☒ QUARTERLY REPORT ...

Financial Performance - Total revenues for Q1 2025 were $7.5 million, a decrease from $17.1 million in Q1 2024, primarily due to a one-time revenue recognition of $6 million in the previous year[8]. - The net loss for Q1 2025 was $20.7 million, or $0.25 per share, compared to a net loss of $11.5 million, or $0.16 per share, in Q1 2024[8]. - The company expects total revenues for 2025 to be in the range of $64 million to $68 million[13]. Research and Development - Research and Development expenses increased to $12.9 million in Q1 2025 from $11.2 million in Q1 2024, driven by higher salaries and lab supplies costs[8]. - Codexis plans to achieve pilot scale production of GLP-grade siRNA material using the ECO Synthesis Innovation Lab in 2025[7]. Contracts and Collaborations - Codexis secured its first revenue-generating contract for ECO Synthesis™ manufacturing services in March 2025[5]. - The company will present at the TIDES USA annual meeting, showcasing its ligase technology and collaborations with leading CDMOs[3][7]. Cash and Investments - As of March 31, 2025, Codexis had $59.8 million in cash, cash equivalents, and short-term investments, sufficient to fund operations through positive cash flow expected by the end of 2026[8][13]. - The company maintained its investment in non-marketable equity securities at $2,798 million[21]. Assets and Liabilities - Total assets decreased from $149,011 million as of December 31, 2024, to $128,887 million as of March 31, 2025, representing a decline of approximately 13.5%[21]. - Current assets fell from $98,772 million to $77,808 million, a decrease of about 21.2%[21]. - Accounts receivable decreased significantly from $11,920 million to $6,442 million, a drop of approximately 46.0%[21]. - Total liabilities decreased from $82,084 million to $79,258 million, a reduction of about 3.4%[21]. - Current liabilities decreased from $23,648 million to $20,901 million, a decline of about 11.7%[21]. - Long-term debt increased slightly from $28,905 million to $29,186 million, an increase of about 1.0%[21]. Stockholders' Equity - Stockholders' equity declined from $66,927 million to $49,629 million, a decrease of approximately 25.9%[21]. - The accumulated deficit increased from $(562,806) million to $(583,494) million, indicating a worsening financial position[21]. Product Performance - Product gross margin improved to 55% in Q1 2025 from 49% in Q1 2024, attributed to a shift towards more profitable products[8]. Leadership Changes - Codexis appointed new board members with extensive experience in biopharmaceuticals and CDMO sectors to strengthen its leadership[5].

Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading CDMO collaborators REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the first quarter ...

Management will host a conference call at 8 am Eastern Time on Thursday, May 22 to discuss data REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will host two data presentations and one poster at the upcoming TIDES USA annual meeting, being held May 19-22, 2025, in San Diego, California. Codexis' presentations will cover a range of topics, including ...